BM

Basel Medical Group Ltd

BMGLHealthcareNASDAQ

Medical Care Facilities

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$11.3M
+12.6% YoY
Net Income
-$10.6M
-613.1% YoY
EBITDA
-$9.7M
-410.9% YoY
Free Cash Flow
-$11.7M

Scan Results

Daily timeframe
4 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 15 MACD Positive CrossoverHistogram +0.0433, positive momentum
Jul 10 MACD Negative CrossoverHistogram -0.0602, negative momentum
About Basel Medical Group Ltd

Basel Medical Group Ltd provides healthcare services in Singapore. Valued at $9.3M, BMGL is a micro-cap name in its sector. The company offers general and subspecialized orthopedic, including trauma and sports medicine services, such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery, and minimally invasive orthopedic procedures, as well as neurosurgical treatments.

Where BMGL stands vs its 150-day and 200-day moving averages

As of the July 15, 2026 close, BMGL finished 5.18% above its 150-day moving average ($7.72) and 20.08% below its 200-day moving average ($10.16). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is BMGL overbought or oversold?

At the July 15, 2026 close, BMGL's RSI(14) was 57.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$9.3M
EPS$-6.46
52W Change-77.5%
ROE-147.4%
Analysis

On the balance sheet, BMGL has $8.4M in cash with $9.9M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company is burning cash, with free cash flow at -$11.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -147.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been relatively flat, moving from $10.7M (2022) to $11.3M (2025).

The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing BMGL.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms
BMGL: Basel Medical Group Ltd Technical Analysis (200-Day MA, RSI, MACD) | Scanance